Page 3 - Erics Lander News Today

Shares of Verastem, Inc. (NASDAQ:VSTM – Get Rating) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among […]

Mizuho initiated coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The firm issued a neutral rating and a $2.00 price objective on the biopharmaceutical company’s stock. Several other research firms have also recently commented on VSTM. Royal Bank of Canada reaffirmed […]

Mizuho initiated coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research report issued on Wednesday, The Fly reports. The brokerage set a “neutral” rating on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target […]

Verastem, Inc. (NASDAQ:VSTM – Get Rating) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,620,000 shares, an increase of 39.7% from the February 28th total of 1,160,000 shares. Based on an average trading volume of 788,100 shares, the days-to-cover ratio is currently […]

StockNews.com began coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research note released on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on VSTM. HC Wainwright reissued a buy rating and issued a $3.00 target price on shares of […]

Stock analysts at Mizuho started coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research note issued to investors on Wednesday, The Fly reports. The brokerage set a “neutral” rating on the biopharmaceutical company’s stock. Several other research firms have also commented on VSTM. HC Wainwright reiterated a “buy” rating and issued a […]

Verastem (NASDAQ:VSTM – Get Rating) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, MarketWatch Earnings reports. Verastem had a negative return on equity of 74.56% and a negative net margin of 3,468.09%. NASDAQ VSTM traded up $0.04 on Wednesday, […]

StockNews.com downgraded shares of Verastem (NASDAQ:VSTM – Get Rating) from a hold rating to a sell rating in a research report released on Monday. Separately, Truist Financial initiated coverage on Verastem in a report on Wednesday, March 9th. They set a buy rating and a $6.00 price objective for the company. One investment analyst has […]

Dr. Collins will temporarily serve in one of the two roles previously held by Dr. Eric S. Lander, who resigned last week.

President Biden came into office vowing to respect science, but openings in crucial jobs could hamper progress on medical and technological research.